As of a. The deal is expected to close sometime in the first quarter ofaccording to the press Agiliti Company. The big deal is that this transaction adds yet another potential megablockbuster product to Novartis' rapidly growing lineup of cutting-edge products. Specifically, the Swiss pharma titan will gain the rights to the experimental cholesterol-lowering medicine inclisiran -- an RNA-interference therapy originally developed by Alnylam Pharmaceuticals and later licensed out to The Medicines Company.

Inclisiran's competitive edge, in theory, stems from its ability to be Medicines Company Stock Price far less frequently than these first-generation therapies. Inclisiran, by contrast, can be administered just once every six months -- a feature that could significantly boost adherence rates. Nov 25, at AM. Author Bio George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since His primary interests are novel small molecule Medicines Company Stock Price, next generation vaccines, and cell therapies.

Image Source: Getty Images. Stock Medicines Company Stock Price launched in February of Join Stock Advisor.

Related Articles.

Search Nasdaq

Yes! I would like to receive Nasdaq communications related to Products, Industry News and Events. You can always change your preferences or unsubscribe and your contact information is covered by ...…

MDCO - Medicines Company Stock Price - Barchart.com

Medicines Company stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.…